Bioject signs second licence agreement with Amgen

Published: 18-Apr-2002


Bioject Medical Technologies, based in Portland, Oregon, US, a leading developer of needle-free drug delivery systems, has signed a second agreement with biotechnology company Amgen to broaden Amgen's potential use of Bioject's needle-free injection systems.

The new contract follows an initial clinical supply and licence agreement with Amgen signed in March 2000 and will provide Amgen with an exclusive licence for use of a modified version of the Bioject B2000 needle-free injection system for certain undisclosed therapeutics. Bioject's needle-free injection systems enable medications and vaccines to be injected into the skin or muscle without the use of needles.

Powered by a compressed CO2 cartridge, Bioject's B2000 technology is a reusable needle-free injector approved for subcutaneous and intramuscular injections. The device comes in two parts; a hand-held reusable jet injector and disposable, plastic syringes. It can deliver a variety of drugs in volumes up to 1ml. The B2000 is the only needle-free device cleared by the FDA to perform intramuscular injections.

You may also like